ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs

ITM Isotope Technologies published Phase 3 COMPETE results in The Lancet, reporting that non-carrier-added [177Lu] edotreotide (ITM-11) significantly improved progression-free survival versus everolimus in 309 patients with Grade 1/2 SSTR-positive GEP-NETs. Patients were randomized 2:1 to [177Lu] edotreotide every 3 months (up to four cycles) versus everolimus daily (up to 30 months), with 21% receiving concomitant SSA therapy. The peer-reviewed publication positions [177Lu] edotreotide as a potential post-SSA option given the unmet need and supports consideration in advanced GEP-NETs.

Analysis

This is more important as a class-validation event than as an immediate earnings driver. The key mechanism is not just substitution against an oral oncology incumbent; it is earlier-line normalization of PRRT, which can expand the addressable pool for the whole SSTR-positive ecosystem over 6-18 months if guidelines and reimbursement follow. The first read-through is negative for everolimus economics, but the larger market impact is likely on treatment sequencing rather than on near-term revenue.

The cleaner beneficiaries are the diagnostic and infrastructure layers that sit in front of PRRT: SSTR PET tracers, nuclear medicine workflows, and treatment-center capacity. Lantheus (LNTH) looks better positioned on a relative basis because broader PRRT adoption should increase scan volumes and referral capture, while the supply bottleneck may become isotope production and center throughput rather than drug demand. Novartis (NVS) is a mixed read: modest pressure on its oral sequencing franchise, but also a potential halo for its radioligand platform if the class grows.

The contrarian risk is that investors may be overestimating the speed of share shift. Better PFS in a controlled trial rarely converts quickly in this niche; adoption depends on tolerability, logistics, dosimetry capability, payer policy, and whether physicians move treatment earlier. Over the next 1-3 months the catalyst is regulatory/guideline chatter, not sales data; over 6-18 months the falsifiers are weak real-world uptake, no reimbursement expansion, or competing PRRT data that re-anchor share back to incumbent options.

Key Decisions for Investors

• Long LNTH / short NVS as a relative-value expression of broader PRRT adoption; 1-3 month horizon, with the thesis that imaging and referral volumes inflect faster than everolimus erosion. Stop if NVS shows no share pressure in neuroendocrine sequencing or if LNTH fails to confirm volume acceleration in the next update.
• Do not chase a standalone long in ITM-related exposure here; wait for a regulatory filing, label language, or reimbursement signal before underwriting any durable revenue impact. This is a watchlist event, not yet a high-conviction catalyst.
• If you want biotech beta, wait for a pullback in XBI/IBB rather than buying the headline response; the read-through is narrow and likely to be mispriced as broad oncology enthusiasm. Use only if broader risk appetite is confirmed by volume and follow-through.
• Set an alert on NVS near-term commentary for everolimus/NET sequencing and on LNTH for SSTR PET volume growth; those are the fastest falsifiers or confirmations of the class-expansion thesis.